Skip to main content

Table 4 Melanoma metastases immune infiltration in the two clinical benefit groups

From: Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients

 

Durable benefit

No benefit

Total

Count

%

Count

%

Count

%

Pattern of T cell infiltration

 A

0

0

1

9.1

1

5.5

 B

6

85.7

6

54.5

12

66.6

 C

1

14.3

2

18.2

3

16.6

 Heterogenous

0

0

2

18.2

2

11.1

Total

7

100

11

100

18

100

CD20+ cells

 No

2

28.6

8

72.7

10

55.5

 Yes

5

71.4

3

27.3

8

44.4

 Total

7

100

11

100

18

100

CD8_PD-L1 pattern

 A

2

28.6

6

50

8

42.1

 B

5

71.4

6

50

11

57.9

 Total

7

100

12

100

19

100